Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Integrating Loco-Regional Hyperthermia in Clinical Oncology"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 3580
Special Issue Editors
E-Mail Website1 Website2
Interests: hyperthermia; hyperthermal biophysics; cancer biophysics; hyperthermia technics; bioelectromagnetism; fractal physiology
Interests: radiotherapy; hyperthermia; radiotherapy infrastructure; LMICs; brachytherapy; meta-analysis; telemedicine
2. Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland
Interests: evidence-based thermotherapy/hyperthermia in oncology; clinical thermoradiotherapy; hardware–software innovations in thermotherapy/hyperthermia; multidisciplinary clinical oncology; radiation oncology infrastructure in LMI countries
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Oncologic HT is a well-known, but only partially established, therapeutic modality that is combined with systemic therapy and/or local radiotherapy in the global oncology community. Its acceptance has been slow over the last 20 years, primarily due to a lack of evidence-based preclinical and clinical research data. However, in recent years, due to advances in biology, physics, technology, and clinical oncology, its acceptance in the oncology community has grown. The reimbursement policies for oncologic hyperthermia in an increasing number of national health care systems support the recognition processes.
The emerging complementary applications synergize different methods, increase their capabilities, and open new perspectives in the field of oncotherapies. Hyperthermia at 39°– 45°C sensitizes tumors to conventional therapies even in refractory cases, while typical other treatments promote cell distortion in addition to thermal degradation. Hyperthermia produces higher chemical reaction rates and better membrane permeability and impacts the cell cycle of the proliferating malignancy. Furthermore, hyperthermia reduces the adverse effects of conventional treatments, and its suppressed toxicity increases the patient's quality of life.
Two main categories of local-regional hyperthermia offer heating possibilities:
• The homogeneous heating of the tumor mass with isothermal intent;
• The selective energy absorption of various inserted artificial particles (mostly nanoparticles) or selecting natural compounds in the heterogenic target.
Intensive research covers the preclinical and clinical applications of bimodal and multimodal therapies, confirming high-level expectations. The previously observed abscopal effect of conventional treatments became a curative goal with immune activation in complementary therapy combinations, thereby opening a new perspective for advanced metastatic diseases. In this way, oncological hyperthermia provides a novel vision in immuno-oncology, extending radiotherapy from local to systemic and improving the systemic processes of various drugs.
This Special Issue summarises results and explores the achievements and trends of research on local oncologic hyperthermia, including various heating methods. The articles explore and discuss numerous challenges and solutions, including the promising effects complementing both conventional and new oncotherapies.
Prof. Dr. András Szász
Prof. Dr. Niloy R. Datta
Prof. Dr. Stephan Bodis
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- multimodal therapies
- abscopal effect
- quality of life
- immune activity
- impact on metastases